CAPLIPOINTPharmaceuticals
Caplin Point Laboratories Ltd — Cash Flow Statement
₹1504.80
-3.75%
Caplin Point Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 240.85 Cr | 172.57 Cr | 77.90 Cr | 245.55 Cr | — |
| Issuance Of Capital Stock | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.03 Cr | — |
| Capital Expenditure | -191.52 Cr | -145.82 Cr | -193.47 Cr | -91.18 Cr | — |
| End Cash Position | 193.74 Cr | 138.55 Cr | 177.56 Cr | 150.76 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -5.71 Cr | -0.15 Cr | — | -8.23 Cr | -4.61 Cr |
| Beginning Cash Position | 138.70 Cr | 177.56 Cr | 150.76 Cr | 231.57 Cr | — |
| Effect Of Exchange Rate Changes | 1.43 Cr | 0.86 Cr | 1.18 Cr | -0.09 Cr | — |
| Changes In Cash | 59.32 Cr | -39.72 Cr | 25.62 Cr | -80.72 Cr | — |
| Financing Cash Flow | -38.32 Cr | -38.07 Cr | -28.17 Cr | -40.68 Cr | — |
| Interest Paid Cff | -0.61 Cr | -0.78 Cr | -0.78 Cr | -0.70 Cr | — |
| Cash Dividends Paid | -37.99 Cr | -34.17 Cr | -30.32 Cr | -22.69 Cr | — |
| Net Common Stock Issuance | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.03 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -3.46 Cr | -0.86 Cr | -1.18 Cr | 0.04 Cr | — |
| Gain Loss On Sale Of PPE | 3.76 Cr | 0.65 Cr | 0.36 Cr | 1.17 Cr | — |
| Net Income From Continuing Operations | 676.78 Cr | 564.43 Cr | 451.35 Cr | 385.82 Cr | — |
| Common Stock Issuance | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.03 Cr | — |
| Net Issuance Payments Of Debt | 0.27 Cr | -3.13 Cr | 2.91 Cr | -16.56 Cr | — |
| Net Long Term Debt Issuance | 0.27 Cr | -3.13 Cr | 2.91 Cr | -16.56 Cr | — |
| Investing Cash Flow | -334.73 Cr | -320.04 Cr | -217.58 Cr | -376.77 Cr | — |
| Net Other Investing Changes | 3.90 Cr | 2.03 Cr | 1.83 Cr | -104.93 Cr | — |
| Interest Received Cfi | 51.72 Cr | 43.73 Cr | 26.82 Cr | 19.60 Cr | — |
| Net Investment Purchase And Sale | -198.83 Cr | -219.98 Cr | -52.76 Cr | -200.26 Cr | — |
| Net PPE Purchase And Sale | -191.52 Cr | -145.82 Cr | -193.47 Cr | -91.18 Cr | — |
| Operating Cash Flow | 432.37 Cr | 318.39 Cr | 271.37 Cr | 336.73 Cr | — |
| Taxes Refund Paid | -130.60 Cr | -109.00 Cr | -88.00 Cr | -81.50 Cr | — |
| Change In Working Capital | -119.32 Cr | -139.44 Cr | -103.75 Cr | 1.96 Cr | — |
| Change In Other Current Assets | -29.70 Cr | 6.74 Cr | 2.33 Cr | 7.23 Cr | — |
| Change In Payable | -28.81 Cr | 77.30 Cr | 31.83 Cr | 83.74 Cr | — |
| Change In Inventory | 26.94 Cr | -74.82 Cr | -60.90 Cr | -48.31 Cr | — |
| Change In Receivables | -87.75 Cr | -148.66 Cr | -77.01 Cr | -40.70 Cr | — |
| Other Non Cash Items | -65.13 Cr | -48.51 Cr | -36.22 Cr | -23.58 Cr | — |
| Stock Based Compensation | 9.38 Cr | 0.85 Cr | 5.19 Cr | 6.67 Cr | — |
| Depreciation And Amortization | 65.96 Cr | 53.44 Cr | 44.99 Cr | 46.90 Cr | — |
| Depreciation | 65.96 Cr | 53.44 Cr | 42.64 Cr | 46.90 Cr | — |
| Gain Loss On Investment Securities | -5.01 Cr | -2.90 Cr | -1.29 Cr | -0.76 Cr | — |
| Sale Of Investment | — | 0.38 Cr | 92.18 Cr | 0.90 Cr | 51.58 Cr |
| Purchase Of Investment | — | -122.24 Cr | -141.25 Cr | -200.26 Cr | -21.24 Cr |
| Net Business Purchase And Sale | — | 0.00 | 0.00 | — | — |
| Purchase Of Business | — | 0.00 | 0.00 | — | — |
| Purchase Of PPE | — | -145.82 Cr | -193.47 Cr | — | — |
| Amortization Cash Flow | — | 2.46 Cr | 2.35 Cr | 1.71 Cr | 1.16 Cr |
| Net Preferred Stock Issuance | — | — | — | — | 0.00 |
| Preferred Stock Issuance | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Caplin Point Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.